Literature DB >> 3966916

Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.

A R Boobis, S Murray, C E Hampden, D S Davies.   

Abstract

A sensitive, specific assay utilizing fluorescence-HPLC has been developed for determining the 1'-hydroxylation of bufuralol by human liver. The 1'-hydroxylation of the isomers of bufuralol varied threefold, both the Vmax and the Km for the (+) isomer being greater than the corresponding values for the (-) isomer. Debrisoquine was a competitive inhibitor of the 1'-hydroxylation of both isomers and of the racemate of bufuralol. Both isomers and the racemate of bufuralol were competitive inhibitors of debrisoquine 4-hydroxylase activity. The competitive inhibition of debrisoquine and bufuralol of each other's metabolism, together with the similarity in the values for Km and Ki, support the conclusion that the same form of cytochrome P-450 catalyses these two reactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966916     DOI: 10.1016/0006-2952(85)90101-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

Authors:  G Smith; S Modi; I Pillai; L Y Lian; M J Sutcliffe; M P Pritchard; T Friedberg; G C Roberts; C R Wolf
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

5.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

6.  Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

Authors:  G Mikus; H R Ha; S Vozeh; C Zekorn; F Follath; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

Authors:  G C Kahn; A R Boobis; M J Brodie; E L Toverud; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

9.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

10.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.